Previous radiotherapy to % or more of the bone marrow and/or radiation therapy within  days prior to study entry
Prior radiation therapy is allowed to < % of the bone marrow, but is not permitted within  days prior to study registration
Concurrent malignancy requiring active therapy\r\n* Patients with localized prostate cancer having undergone surgery or radiation (field confined to =< % of marrow-bearing bone) at least  days prior to study treatment are eligible
Patients who have received radiation to more than % of marrow-bearing areas
No prior radiation to > % of the marrow.
Prior radiotherapy within  weeks of the first dose of study treatment; patients who have received radiation to more than % of the bone marrow are not eligible at any time
Patients must not have received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG; prior dexamethasone and/or surgery are allowed
Participants who have received prior radiation therapy to > % of the bone marrow.
The patient has received radiation to ? % of his or her bone marrow within  weeks of the first dose of study drug.
Prior treatment with radiation therapy involving >=% of the hematopoietically active bone marrow within  months before the first dose of study drug.
Patients must not have had radiotherapy encompassing > % of the bone marrow within  weeks; or any radiation therapy within  week prior to day  of protocol therapy
If the patient received previous radiation therapy, the total absorbed radiation dose at the bone marrow level must be ?  Gy
Radiation therapy to >% of bone marrow prior to study entry;
Prior radiation therapy for treatment of cancer is allowed to <% of the bone marrow.
Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Patients who have received either immunotherapy within =<  weeks; chemotherapy within =<  weeks; or radiation therapy to > % of marrow-bearing bone within =<  weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Prior pelvic radiation therapy or patients who have undergone prior radiation to greater than or equal to % of the bone marrow within the past year are excluded; patients who received radiation for prostate cancer are also excluded
Subjects who have received radiation therapy targeting > % of the bone marrow space must have completed this at least  weeks prior to starting therapy with DSb
History of radiation therapy to >= % of the bone marrow for other diseases
Having received immunotherapy or chemotherapy within  weeks; or radiation therapy to > % of marrow-bearing bone within =<  weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Radiation therapy to more than % of the bone marrow
Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Subjects who have received radiation therapy targeting > % of the bone marrow space must have completed this at least  weeks prior to starting therapy with AMG- + KRd
Prior radiation therapy irradiating more than % of total bone marrow
Participants may not have had radiation to > % of the bone marrow
Prior abdominal or pelvic radiation therapy or radiation therapy to > % of the bone\n             marrow at any time in the past or prior radiation therapy within the past  years to\n             the breast/sternum, dermal lesions, head or neck.
 weeks if other bone marrow radiation has been administered.
No history of radiation therapy to >= % of the bone marrow for other diseases or history of anthracycline therapy
Prior radiation therapy encompassing > % of bone marrow
Patients cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids (greater than the equivalent of  mg prednisone per day), or radiation therapy to > % of the bone marrow, within  months of the first vaccination; treatment or salvage radiation therapy encompassing =< % of bone marrow must have been completed  weeks prior to the first vaccination
Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Participant has received irradiation to a major bone marrow area as defined as > % of bone marrow (such as, pelvic or abdominal radiation) within  days prior to randomization
Patients who have received chemotherapy or radiation therapy to > % of marrow bearing bone within <  weeks or experimental agent/therapy within  weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Radiation therapy (other than palliative) =<  weeks prior to randomization; note: patients who have had > % of their functional bone marrow irradiated are not eligible for this trial
Has received prior radiation to > % of the bone marrow
Patient must not have had radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %; (ongoing small field radiation therapy for palliation only is allowed)
Patients who have received either immunotherapy within =<  weeks; chemotherapy within =<  weeks; or radiation therapy to > % of marrow-bearing bone within =<  weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Patients who have received chemotherapy within </=  weeks by time of cycle  day  of therapy on trial ; or radiation therapy to > % of marrow-bearing bone within  weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies.
Patients who have received radiation to more than % of marrow-bearing areas
Radiation therapy to greater than % of the bone marrow
Radiation therapy to more than % of the bone marrow (note: whole pelvic radiation is considered to be over %)
prior radiation therapy with volume of bone marrow treated over %.
Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Patients who have received either immunotherapy within =<  weeks; chemotherapy within =<  weeks; or radiation therapy to > % of marrow-bearing bone within =<  weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Prior radiation therapy allowed to < % of the bone marrow
Prior treatment with radiation therapy involving ? % of the hematopoietically active bone marrow within  days before the first dose of study drug.
Prior treatment with radiation therapy involving >=  percent (%) of hematopoietically active bone marrow.
Focal radiation therapy within  days prior to randomization; radiation therapy to an extended field involving a significant volume of bone marrow within  days prior to randomization (i.e., prior radiation must have been to less than % of the bone marrow)
Prior treatment with radiation therapy involving ? % of the hematopoietically active bone marrow
Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Radiation therapy to % of bone marrow within  weeks of first dose
Patients who have received either immunotherapy within =<  weeks; chemotherapy within =<  weeks; or radiation therapy to > % of marrow-bearing bone within =<  weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Focal radiation therapy within  days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within  days prior to randomization (i.e., prior radiation must have been to less than % of the bone marrow).
Patients must have had at least  prior systemic chemotherapy (not just steroids or local radiation); last chemotherapy or radiation must be at least  weeks prior to enrollment on this study; patients who decline other potentially curative therapy may be eligible; prior radiation therapy must not have been to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Received radiation therapy to more than % of the bone marrow-containing spaces <  days prior to first dose of study medication
Patients who have received either immunotherapy within =<  weeks; chemotherapy within =<  weeks; or radiation therapy to > % of marrow-bearing bone within =<  weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
Prior radiation therapy to < % of the bone marrow [see bone marrow radiation chart in the study procedure manual (SPM)] allowed if completed within  days prior to registration for protocol therapy.
Prior radiation to ? % of bone marrow or any radiation therapy within  days prior to randomization
Radiation therapy to more than % of the bone marrow; whole pelvic radiation is considered to be over %
Diagnosis of another primary cancer for which the patient is currently undergoing radiation therapy, chemotherapy, or bone marrow transplant
Current systemic chemotherapy or radiation therapy that potentially causes bone marrow suppression that would preclude safe treatment of HSIL
Prior radiation therapy is allowed; patients must not have received any radiation within  weeks prior to the initiation of study treatment; patients may not have areas of irradiated marrow exceeding % of bone marrow volume
Prior treatment with radiation therapy involving greater than or equal to (>=) % of the hematopoietically active bone marrow.
The patient has received radiation to ? % of his or her bone marrow within  weeks of the first dose of study drug.
